X0609 4 2026-10-01 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001794898 King-Jones Heidy false 221 CRESCENT STREET, BUILDING 23, SUITE 105 WALTHAM MA 02453 0 1 0 0 See Remarks 1 Common Stock 2026-10-01 4 M 0 28933 14.50 A 31778 D Common Stock 2026-10-01 4 S 0 400 89.24 D 31378 D Common Stock 2026-10-01 4 S 0 16605 90.35 D 14773 D Common Stock 2026-10-01 4 S 0 7228 91.35 D 7545 D Common Stock 2026-10-01 4 S 0 2100 92.70 D 5445 D Common Stock 2026-10-01 4 S 0 2600 93.46 D 2845 D Stock Option (Right to Buy) 14.50 2026-10-01 4 M 0 28933 0 D 2033-09-01 Common Stock 28933 482478 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Chief Legal Officer and Corporate Secretary /s/ Heidy King-Jones 2026-10-02